Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 359 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: DEXA Clear all
Active, not recruiting Phase 1 Interventional

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

NCT06042725
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Computed Tomography, Daratumumab, Dexamethasone, Lenalidomide, Low Dose Computed Tomography of the Whole Body, Magnetic Resonance Imaging, Positron Emission Tomography, Venetoclax, X-Ray Imaging, Questionnaire Administration
Procedure · Biological · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 21, 2026, 9:22 PM EDT
Completed No phase listed Observational

Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture

NCT02355340
View directory record Official record
Conditions
Bone Mineral Density, Childhood Cancer Survivors
Interventions
Dual energy x-ray absorptiometry (DXA), Peripheral quantitative computed tomography (pQCT)
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
8 Years to 20 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 21, 2026, 9:22 PM EDT
Active, not recruiting Phase 4 Interventional

Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI

NCT05101018
View directory record Official record
Conditions
Osteoporosis, Spinal Cord Injuries
Interventions
Romosozumab, Denosumab
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 21, 2026, 9:22 PM EDT
Terminated Phase 1 Interventional Results available

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

NCT03031730
View directory record Official record
Conditions
Plasmacytoma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Carfilzomib, Dexamethasone, Dexamethasone Sodium Phosphate, Echocardiography, Lenalidomide, Navtemadlin
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
7
States / cities
Sacramento, California • Aurora, Colorado • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 21, 2026, 9:22 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00720109
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Interventions
Asparaginase, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Filgrastim, Hydrocortisone Sodium Succinate, Ifosfamide, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisone, Radiation Therapy, Vincristine Sulfate
Drug · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 30 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
118
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 21, 2026, 9:22 PM EDT
Terminated Phase 2 Interventional

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

NCT04352205
View directory record Official record
Conditions
Plasma Cell Myeloma, Renal Failure
Interventions
Bortezomib, Daratumumab, Dexamethasone, Lenalidomide, Thalidomide
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 21, 2026, 9:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Spinal Cord Stimulation for Restless Legs Syndrome

NCT03539081
View directory record Official record
Conditions
Restless Legs Syndrome, Neuropathic Pain
Interventions
Dual-energy X-ray absorptiometry Scan, Laboratory Measurements, Blood Flow Measurement, Continuous Blood Pressure, Partial pressure of oxygen, Microneurography, Anthropometric Measurements, John Hopkins Restless Legs Severity Scale, Continuous Blood Pressure Diary
Diagnostic Test · Other · Behavioral
Lead sponsor
Marshall Holland
Other
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 21, 2026, 9:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Comparative Effectiveness Study Evaluating the Effects of Thermogenic Supplements on Body Composition

NCT01423019
View directory record Official record
Conditions
Weight Loss
Interventions
Advantra Z, Advantra Z + Naringin + Hesperiden, Sugar pill
Dietary Supplement · Other
Lead sponsor
Integrative Health Technologies, Inc.
Network
Eligibility
21 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2012 · Synced Oct 21, 2026, 9:22 PM EDT
Recruiting Not applicable Interventional

Feasibility and Adherence to a Technology-assisted Home-based Strength Training Program in Adults With Type 2 Diabetes Mellitus and Mild Cognitive Impairment

NCT07416799
View directory record Official record
Conditions
Type2diabetes, Mild Cognitive Impairment, Age-related Cognitive Decline
Interventions
Progressive Exercise Program (12 Weeks)
Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
55 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 21, 2026, 9:22 PM EDT
Completed Not applicable Interventional

Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors

NCT00580281
View directory record Official record
Conditions
Gastric Cancer, Leukemia, Chronic Myelogenous Leukemia
Interventions
blood test, urine test, and bone density x-ray.
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Oct 21, 2026, 9:22 PM EDT
Terminated Phase 1 Interventional

Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

NCT04156828
View directory record Official record
Conditions
Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
Interventions
Copanlisib, Gemcitabine, Carboplatin, Dexamethasone, Rituximab, Pegfilgrastim
Drug · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 21, 2026, 9:22 PM EDT
Terminated Phase 2Phase 3 Interventional

Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

NCT00675714
View directory record Official record
Conditions
Burns
Interventions
Stable Isotope Infusion Study, Collection of blood and tissues, Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI, Humatrope, Ketoconazole, Oxandrolone, Propranolol, Oxandrolone and propranolol combined, Humatrope and propranolol combined, Placebo, Exercise--Hospital supervised intensive exercise program, Home exercise program
Procedure · Drug · Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 80 Years
Enrollment
1,126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 21, 2026, 9:22 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study

NCT05216042
View directory record Official record
Conditions
Cardiovascular Diseases, Natriuretic Peptides, Cardiometabolic Diseases, Energy Expenditure, Glucose Metabolism, Exercise, Obesity
Interventions
Study diet, Exercise capacity VO2 max determination, Exercise Challenge, Glucose Challenge
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 9:22 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT05032183
View directory record Official record
Conditions
Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Lymphoblastic Lymphoma, Refractory T Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide, Cytarabine, Dexamethasone, Filgrastim-sndz, Leucovorin, Mercaptopurine, Mesna, Methotrexate, Pegfilgrastim, Prednisone, Rituximab, Tagraxofusp-erzs, Vincristine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 21, 2026, 9:22 PM EDT
Active, not recruiting Phase 1 Interventional

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

NCT03132454
View directory record Official record
Conditions
Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Decitabine, Dexamethasone, Palbociclib, Sorafenib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 9:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Targeted Protein Fortification in Extremely Low Birth Weight Preterm Infants

NCT02943746
View directory record Official record
Conditions
Premature Infants
Interventions
Standard Protein Diet, High Protein Diet
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
14 Days and older
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 21, 2026, 9:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

NCT02356159
View directory record Official record
Conditions
Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Leukemia, Multiple Myeloma
Interventions
Rituximab, Conditioning chemotherapy, TMS, FLAG, EPOCH-F, Hematopoietic stem cell transplant, Palifermin, Acetaminophen, Diphenhydramine, Prednisone, Epinephrine, IV Saline, ECG, ECHO, MUGA, DEXA, CT chest, PET, MRI, BM aspirate, BM biopsy, Lumbar puncture
Biological · Drug · Procedure + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 21, 2026, 9:22 PM EDT
Recruiting Not applicable Interventional

Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial

NCT05236062
View directory record Official record
Conditions
Graft Vs Host Disease, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease
Interventions
Exercise, Attention control
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 21, 2026, 9:22 PM EDT
Completed Phase 1 Interventional Results available

Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)

NCT00866307
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Prophylactic Cranial Irradiation, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
25
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 21, 2026, 9:22 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Mechanisms for Activation of Beige Adipose Tissue in Humans

NCT04666636
View directory record Official record
Conditions
PreDiabetes
Interventions
Placebo, Mirabegron, Mirabegron 50 MG, Mirabegron 100 mg
Drug
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 21, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen

NCT02478632
View directory record Official record
Conditions
HIV Infections
Interventions
Subjects do not receive study medication in this study 202094
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 21, 2026, 9:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of Clinical Methods to Evaluate Neural Function in Aging

NCT02073201
View directory record Official record
Conditions
Aging
Interventions
High-functioning older adults, Lower-functioning older adults, Young adults
Other
Lead sponsor
University of Florida
Other
Eligibility
20 Years to 100 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 21, 2026, 9:22 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease

NCT04508088
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn Disease
Interventions
Coronal T1 weighted spin echo images, Spin-lattice relaxation (T1), Magnetic resonance spectroscopy, Blood Draw
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
13 Years to 20 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 21, 2026, 9:22 PM EDT
Terminated Phase 2 Interventional Results available

Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab

NCT04407442
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Azacitidine, Daratumumab, Dexamethasone
Drug · Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 21, 2026, 9:22 PM EDT